Small-molecule survivin inhibitor YM155 enhances radiosensitization in esophageal squamous cell carcinoma by the abrogation of G2 checkpoint and suppression of homologous recombination repair
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Small-molecule survivin inhibitor YM155 enhances radiosensitization in esophageal squamous cell carcinoma by the abrogation of G2 checkpoint and suppression of homologous recombination repair
Authors
Keywords
Survivin, YM155, Radiosensitization, ESCC, G2 checkpoint, Homologous recombination repair
Journal
Journal of Hematology & Oncology
Volume 7, Issue 1, Pages -
Publisher
Springer Nature
Online
2014-08-19
DOI
10.1186/s13045-014-0062-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Smac mimetic compound LCL161 sensitizes esophageal carcinoma cells to radiotherapy by inhibiting the expression of inhibitor of apoptosis protein
- (2013) Qin Qin et al. TUMOR BIOLOGY
- YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model
- (2011) Takahito Nakahara et al. ANTI-CANCER DRUGS
- Treating Cutis Verticis Gyrata Using Skin Expansion Method
- (2011) Donghong Zhao et al. CELL BIOCHEMISTRY AND BIOPHYSICS
- Antitumor Activity of YM155, a Selective Small-Molecule Survivin Suppressant, Alone and in Combination with Docetaxel in Human Malignant Melanoma Models
- (2011) Kentaro Yamanaka et al. CLINICAL CANCER RESEARCH
- Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma
- (2011) Aya Kita et al. LEUKEMIA RESEARCH
- Survivin inhibition and DNA double-strand break repair: A molecular mechanism to overcome radioresistance in glioblastoma
- (2011) Sebastian Reichert et al. RADIOTHERAPY AND ONCOLOGY
- High expression of survivin predicts poor prognosis in esophageal squamous cell carcinoma following radiotherapy
- (2011) Hongxia Zhu et al. TUMOR BIOLOGY
- Mechanism of Radiosensitization by the Chk1/2 Inhibitor AZD7762 Involves Abrogation of the G2Checkpoint and Inhibition of Homologous Recombinational DNA Repair
- (2010) Meredith A. Morgan et al. CANCER RESEARCH
- Targeting Polo-like Kinase in Cancer Therapy
- (2010) Y. Degenhardt et al. CLINICAL CANCER RESEARCH
- Prognostic significance of survivin expression in renal cell cancer and its correlation with radioresistance
- (2010) Yu Lei et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Down-regulation of survivin by oxaliplatin diminishes radioresistance of head and neck squamous carcinoma cells
- (2010) Zakir Khan et al. RADIOTHERAPY AND ONCOLOGY
- Adenovirus-mediated transfer of siRNA against survivin enhances the radiosensitivity of human non-small cell lung cancer cells
- (2009) C-T Yang et al. CANCER GENE THERAPY
- Survivin as a Prognostic Marker for Urothelial Carcinoma of the Bladder: A Multicenter External Validation Study
- (2009) S. F. Shariat et al. CLINICAL CANCER RESEARCH
- Radiosensitizing Effect of YM155, a Novel Small-Molecule Survivin Suppressant, in Non-Small Cell Lung Cancer Cell Lines
- (2008) T. Iwasa et al. CLINICAL CANCER RESEARCH
- Targeting survivin in cancer therapy
- (2008) Marzia Pennati et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Nuclear survivin expression predicts poorer prognosis in glioblastoma
- (2008) Katsuyuki Shirai et al. JOURNAL OF NEURO-ONCOLOGY
- AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies
- (2008) S. D. Zabludoff et al. MOLECULAR CANCER THERAPEUTICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now